The shares of Mattel, Inc. (NASDAQ:MAT) has been pegged with a rating of Neutral by UBS in its latest research note that was published on June 19th, 2018. UBS wasn’t the only research firm that published a report of Mattel, Inc., with other equities research analysts also giving their opinion on the stock. Jefferies advised investors in its research note published on April 11th, 2018, to Hold the MAT stock. The stock had earned Underperform rating from Jefferies when it published its report on February 26th, 2018. The stock was given Buy rating by Citigroup in its report released on February 6th, 2018, the day when the price target on the stock was placed at $20. B. Riley FBR, Inc. was of a view that MAT is Neutral in its latest report on December 21st, 2017 while giving it a price target of $15. Stifel thinks that MAT is worth Hold rating. This was contained in the firm’s report on December 13th, 2017 in which the stock’s price target was also moved to $14.

Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 11 believe it has the potential for further growth, thus rating it as Hold while 2 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $14.52. The price of the stock the last time has raised by 46.97% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 45.60.

The shares of the company added by 1.29% during the trading session on Tuesday, reaching a low of $12.93 while ending the day at $13.36. During the trading session, a total of 4.75 million shares were traded which represents a 21.26% incline from the average session volume which is 6.03M shares. MAT had ended its last session trading at 13.19. Mattel, Inc. currently has a market cap of $4.60B while its P/E earnings growth sits at 1.02, with a beta of 1.44. Mattel, Inc. debt-to-equity ratio currently stands at 4.27, while its quick ratio hovers at 1.40. MAT 52-week low price stands at $9.09 while its 52-week high price is $17.98.

The company in its last quarterly report recorded $0.04 earnings per share which is above the -$0.16 predicted by most analysts. The Mattel, Inc. generated $1,524.30 million in revenue during the last quarter, which is slightly higher than the $1,436.73 million predicted by analysts. In the second quarter last year, the firm recorded $0.18 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -350%. Mattel, Inc. has the potential to record -1.54 EPS for the current fiscal year, according to equities analysts.

Investment analysts at Argus published a research note on March 25th, 2019 where it informed investors and clients that AbbVie Inc. (NYSE:ABBV) is now rated as Hold. Jefferies also rated ABBV as Upgrade on April 11th, 2018, with its price target of $115 suggesting that ABBV could surge by 12.99% from its current share price. Even though the stock has been trading at $81.03/share, analysts expect it to surge higher by -1.01% to reach $92.18/share. It started the day trading at $81.30 and traded between $80.02 and $80.21 throughout the trading session.

A look at its technical shows that ABBV’s 50-day SMA is 80.36 while its 200-day SMA stands at 87.92. At the moment, only of AbbVie Inc. shares were sold short. The company’s average trading volume currently stands at 6.43M shares, which means that the short-interest ratio is just 3.54 days. Over the past seven days, the company moved, with its shift of -3.00%. Looking further, the stock has dropped -6.19% over the past 90 days while it lost -11.56% over the last six months.

The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. Capital Research Management Co sold more ABBV shares, decreasing its portfolio by -1.46% during the last quarter. This move now sees Capital Research Management Co selling -2,571,964 shares in the last quarter, thus it now holds 173,568,243 shares of ABBV, with a total valuation of $13,987,864,703. The Vanguard Group Inc meanwhile bought more ABBV shares in the recently filed quarter, changing its stake to $9,542,899,560 worth of shares. BlackRock Fund Advisors followed the path by decreasing its ABBV portfolio by -1.07% in the quarter. This means that BlackRock Fund Advisors sold -709,441 shares in the last quarter and now controls 65,826,983 shares of the ABBV stock, with the valuation hitting $5,304,996,560.

Similarly, Capital Research Management Co increased its AbbVie Inc. shares by +7.34% during the recently filed quarter. After buying 2,025,965 shares in the last quarter, the firm now controls 29,620,613 shares of AbbVie Inc. which are valued at $2,387,125,202. In the same vein, Northern Trust Investments Inc increased its AbbVie Inc. shares by during the most recent reported quarter. The firm bought 227,408 shares during the quarter which increased its stakes to 21,029,665 shares and is now valued at $1,694,780,702. Following these latest developments, around 0.10% of AbbVie Inc. stocks are owned by institutional investors and hedge funds.